Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes - Authors' reply

Lancet Haematol. 2023 Nov;10(11):e872-e873. doi: 10.1016/S2352-3026(23)00274-0.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cytarabine
  • Daunorubicin
  • Humans
  • Myelodysplastic Syndromes* / drug therapy

Substances

  • CPX-351
  • Daunorubicin
  • Cytarabine